Marti Technologies, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $MRT in the last 7 days.
Freifeld Daniel sold 1,350,000 indirectly-held shares of Marti Technologies, Inc. (MRT) at an average of $1.91 ($1.70–$2.04, $2.58M total) across 3 trades over 2026-05-18 to 2026-09-09.
HC Wainwright initiated coverage of Monte Rosa Therapeutics with a Buy rating and $25 price target, implying 109.6% upside from the Sep 30 close. The company has shown strong clinical data, particularly with MRT-8102, and has partnerships with major pharma firms like Novartis.
Marti Technologies (NYSE American: MRT) increased its share repurchase authorization to $5 million, extending the program through April 2027. The Board set a $6.00 per-share ceiling. As of September 9, 2026, $3.8 million remains available for repurchases, with shares closing at $2.13. Since January 2024, Marti repurchased 795,467 shares at an average price of $1.95, totaling $1.6 million.
Recent MRT coverage spans earnings, financial news and technology.
In the last 30 days, MRT insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($707K). The most active reporter was Freifeld Daniel with 1 filing.
The insider sale may create modest selling pressure on MRT.
Analyst initiation and a high price target are likely to drive buying interest and upward price pressure.
The expanded buyback provides potential upward pressure on the stock as the company can repurchase shares at up to $6.00 per share.
The upward guidance suggests stronger demand and could lift the stock price.
Positive growth metrics may boost investor sentiment and support short‑term price appreciation.
AlphAI scores every news story that mentions MRT with an AI model for sentiment and relevance, and aggregates insider trades from Marti Technologies, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Freifeld Daniel sold 1,350,000 indirectly-held shares of Marti Technologies, Inc. (MRT) at an average of $1.91 ($1.70–$2.04, $2.58M total) across 3 trades over 2026-05-18 to 2026-09-09.
1 min readHC Wainwright initiated coverage of Monte Rosa Therapeutics with a Buy rating and $25 price target, implying 109.6% upside from the Sep 30 close. The company has shown strong clinical data, particularly with MRT-8102, and has partnerships with major pharma firms like Novartis.
1 min readMarti Technologies (NYSE American: MRT) increased its share repurchase authorization to $5 million, extending the program through April 2027. The Board set a $6.00 per-share ceiling. As of September 9, 2026, $3.8 million remains available for repurchases, with shares closing at $2.13. Since January 2024, Marti repurchased 795,467 shares at an average price of $1.95, totaling $1.6 million.
1 min readMarti Technologies (MRT) raised 2026 revenue guidance to $85M and adjusted EBITDA to $7M, citing growth in services and AI. The company operates in 30 cities, serving 8.3M consumers, and is expanding into delivery, financial, and autonomous vehicle sectors.
1 min readMarti Technologies (NYSE American: MRT) reported 4.90 million riders and 584,000 drivers, exceeding September 2026 targets. It aims for 5.65 million riders and 630,000 drivers by December 2026. Growth outside Istanbul increased, covering 30 cities and 85% of Türkiye's GDP. McKinsey estimates the 2030 ride-hailing market at $15B-$20B.
1 min readWall Street analysts updated price targets and ratings for several companies. Baird cut Chipotle's (CMG) target to $40 and downgraded it to Neutral. HC Wainwright raised LB Pharmaceuticals' (LBRX) target to $60. BTIG increased AtriCure's (ATRC) target to $55. Baird also raised Analog Devices' (ADI) target to $675 and upgraded Darden Restaurants' (DRI) target to $250. Other notable changes include updates for Black Rock Coffee Bar (BRCB), Marti Technologies (MRT), Alkami Technology (ALKT), Chenie
2 min readMarti Technologies reported Q2 2026 earnings with 141% revenue growth, first-ever positive adjusted EBITDA, and raised full-year guidance to $85M revenue and $7M EBITDA. The company expanded its ride-hailing footprint, improved gross margins to 77%, and initiated a pivot toward autonomous mobility. Management expects sustainable margins around 80% and plans to expand parcel delivery services.
3 min readMarti Technologies (MRT) reported Q2 2026 revenue of $20M, beating estimates and up 141% YoY. Despite a wider-than-expected adjusted loss of $0.15 per share, the company achieved positive adjusted EBITDA of $2.9M and raised its full-year outlook to $85M in revenue and $7M in adjusted EBITDA. Shares rose 5% in pre-market trading.
2 min readMarti Technologies, Inc. (MRT) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Marti Achieves Record Second Quarter with 141% Revenue Growth, 77% Gross Profit Margin, Significant Improvement in Profitability, and Increased Guidance Ride-hailing growth, platform monetization, and expanding margins drove record profitability and support increased
2 min readMarti Technologies (NYSE American: MRT) said it launched its ride-hailing service in 10 additional Turkish cities, expanding coverage to 30 cities and about 85% of Türkiye’s GDP. The company reported rider and driver shares outside Istanbul rose to 45% and 36% as of Aug. 11, 2026. Marti reiterated FY2026 guidance of $85M revenue and $7M Adjusted EBITDA, expecting accretion starting 2027.
3 min read
